The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Autolus Therapeutics plc(NASDAQ:AUTL) 
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; A...
Website: http://www.autolus.com
Founded: 2014
Full Time Employees: 290
Sector: Healthcare
Industry: Biotechnology
Autolus Therapeutics plc Days Payable Outstanding ttm (DPO)
Autolus Therapeutics plc Days Receivable Outstanding ttm (DSO)
Autolus Therapeutics plc Days Inventory Outstanding ttm (DIO)
Autolus Therapeutics plc Op Cashflow Per Share ttm
Autolus Therapeutics plc Free Cashflow Per Share ttm
Autolus Therapeutics plc Cash Per Share ttm
Autolus Therapeutics plc P/S ratio ttm
Autolus Therapeutics plc (GAAP) P/E ratio ttm
Autolus Therapeutics plc P/B ratio ttm
No extra charts and metrics for this ticker.